Law360, New York (February 3, 2012, 4:53 PM EST) -- A Pennsylvania federal judge on Wednesday granted preliminary approval for the settlement of multidistrict consumer fraud litigation claiming Impax Laboratories Inc.'s generic version of the antidepressant Wellbutrin XL was deceptively labeled and is less effective and more dangerous than the brand-name pill.
The settlement calls for Impax, which developed and manufactures Budeprion XL, and Teva Pharmaceuticals USA Inc., which distributes the drug, to take several injunctive measures consistent with federal regulations relating to the state-law claims asserted against the companies, which were consolidated into an MDL in December 2009.
The measures include removing allegedly misleading labeling information for Budeprion XL, further...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!